New pill combo aims to keep advanced breast cancer in check

NCT ID NCT05876065

Recruiting now Disease control Sponsor: Wenjin Yin Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares a combination of two chemotherapy pills (capecitabine and cyclophosphamide) against standard maintenance treatments for women with advanced breast cancer whose disease is under control after initial therapy. The goal is to see which approach better delays cancer progression. About 86 participants will be randomly assigned to one of the two options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: capecitabine and cyclophosphamide
What this could lead to: If successful, this could offer a new, effective maintenance option to delay disease progression in advanced breast cancer.
What could go wrong: This is a small, early-stage trial (86 participants) with no phase designation, so results may not be conclusive. The combination may cause side effects like hand-foot syndrome or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING

Shanghai, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.